🔬 The Coolest Diffusion Research Isn't in LLMs — Evan Feinberg & Sergey Edunov, Genesis Molecular AI
Latent Space Brandon Anderson
Genesis Molecular AI has developed PEARL, a diffusion-based model that predicts how drug molecules bind to proteins by accounting for protein flexibility and induced-fit dynamics that traditional methods cannot handle. The model achieved superior performance on the OpenBind benchmark of 802 unseen protein-ligand complexes, consistently reaching 1 Ångstrom RMSD accuracy—a threshold necessary for correctly modeling interactions like hydrogen bonds, compared to the field's inadequate 2 Ångstrom standard. This accuracy enables autonomous drug discovery agents to iterate through molecular design cycles continuously, combining computational predictions with automated lab testing to accelerate the search through 10^60 possible drug-like molecules.
Why it matters
Why the Llama lead left Meta for drug discovery, PEARL's zero-shot OpenBind win, and what becomes possible when co-folding finally crosses the accuracy threshold.
Related stories
From In-Silico to Wet-Lab: Evaluating AI Protein Design Performance
MarkTechPost · 1 week ago ·
33
Customized Amazon Nova models improve molecular-property prediction in drug discovery
Amazon Science · 4 months ago ·
48